Tapentadol in Chronic Malignant Tumour Related Pain

This study has been completed.
Information provided by (Responsible Party):
Grünenthal GmbH
ClinicalTrials.gov Identifier:
First received: December 16, 2010
Last updated: July 16, 2014
Last verified: July 2014

The purpose of this trial is the characterization of the long term safety profile and long-term dose requirements of tapentadol PR (prolonged release) in patients with malignant tumor-related pain. In the United States the prolonged-release formulation is also referred to as the extended-release formulation.

Condition Intervention Phase
Chronic Pain
Drug: tapentadol prolonged release
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Open-label, Single-arm, Flexible Dosing, Phase III Trial, With Oral Tapentadol PR in Subjects With Chronic Malignant Tumor-related Pain Who Have Completed the Maintenance Period of the KF5503/15 Trial.

Resource links provided by NLM:

Further study details as provided by Grünenthal GmbH:

Primary Outcome Measures:
  • Frequency and severity of Adverse Events [ Time Frame: From date of first IMP intake until date of 3 days after last IMP intake, assessed up to 4 years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Assess consumption of tapentadol during long term use [ Time Frame: From date of first IMP intake until date of last IMP intake, assessed up to 4 years ] [ Designated as safety issue: Yes ]

Enrollment: 31
Study Start Date: December 2010
Study Completion Date: May 2014
Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tapentadol Prolonged Release
Participants allocated to this treatment arm can be dosed between 100 to 250 mg tapentadol twice daily.
Drug: tapentadol prolonged release
Titration to achieve sufficient pain relief to continue with effective analgesia for as long as the participant tolerates and wishes to continue treatment.
Other Names:
  • Nucynta®
  • Palexia®
  • Yantil®

Detailed Description:

The prevalence of tumor-related pain is high and the treatment of chronic tumor-related pain remains a challenging therapeutic problem.

This is a clinical trial with only 1 treatment group: tapentadol prolonged release 100 mg to 250 mg twice daily.

For subjects who have directly entered the KF5503/52 trial from the KF5503/15 trial (i.e., within 7 days of Visit 8 of the KF5503/15 trial): a Transfer Visit, an Open-label Treatment Period and a Follow-up Period.

For subjects who have a gap of more than 7 days and less than 24 weeks, between their full completion of the KF5503/15 trial and entry into the KF5503/52 trial: an Enrollment Visit, an Entry Visit for assessment of eligibility, an Open-label Treatment Period and a Follow-up Period.

This trial was designed to offer patients with chronic malignant tumor-related pain the option of continuing treatment by receiving tapentadol PR.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects must have signed an Informed Consent Form.
  • At least 18 years of age.
  • Male and non-pregnant, non-lactating female subjects. Sexually active women must be post menopausal, surgically sterile, or practicing an effective method of birth control before entry and throughout the trial. Female subjects of child-bearing potential must have a negative pregnancy test at enrollment.
  • Within 24 weeks of either full completion or completion of the Double-blind Treatment Period (Visit 8) of KF5503/15 trial performed in subjects with moderate to severe chronic malignant tumor related pain.
  • Subject is, in the opinion of the Investigator, expected to continue to have an overall positive benefit/risk ratio from continuing analgesic treatment within this trial.
  • Subjects must be willing to take tapentadol PR throughout their participation in the trial.

Exclusion Criteria:

  • History of alcohol and/or drug abuse.
  • The subject has a clinically significant disease other than cancer that in the Investigator's opinion may affect the safety of the subject.
  • Employees of the Investigator or trial center or family members of the employees or the Investigator.
  • Known to or suspected of not being able to comply with the protocol and the use of tapentadol PR.
  • Concurrent participation in another trial (except for participation in the KF5503/15 trial) or planning to be enrolled in another clinical trial during the course of this trial.
  • Previous participation in another trial between the end of KF5503/15 and enrollment into the current trial, KF5503/52.
  • History of seizure disorder, epilepsy, traumatic brain injury, stroke or transient ischemic attack.
  • Known history and/or presence of cerebral tumors or metastases.
  • Rapidly escalating pain or pain uncontrolled by therapy and was previously treated with maximum (dose level 4) Investigational Medicinal Product dose.
  • Subjects taking any prohibited concomitant medications.
  • Uncontrolled hypertension.
  • Known moderate or severe hepatic impairment.
  • Known severe renal impairment.
  • Clinically relevant history of hypersensitivity, allergy, or contraindications to tapentadol or its excipients.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01264887

Site 359004
Shoumen, Bulgaria, 9700
Site 036002
Nyiregyhaza, Hungary, 4412
Site 036010
Szekszard, Hungary, 7100
Moldova, Republic of
Site 373001
Chisinau, Moldova, Republic of, 2025
Site 048004
Bydgoszcz, Poland, 85796
Site 048001
Warszawa, Poland, 02781
Site 040006
Brasov, Romania, 500074
Site 040002
Bucharest, Romania, 022328
Russian Federation
Site 007007
Nizhniy Novgorod, Russian Federation, 603140
Site 007012
Vladikavkaz, Russian Federation, 362007
Site 381002
Nis, Serbia, 18000
Site 381001
Sremska Kamenica, Serbia, 21204
Sponsors and Collaborators
Grünenthal GmbH
Principal Investigator: Hans-Georg Kress, Prof. Dr. med General Hospital Vienna
  More Information

No publications provided

Responsible Party: Grünenthal GmbH
ClinicalTrials.gov Identifier: NCT01264887     History of Changes
Other Study ID Numbers: 168935, 2009-013291-46
Study First Received: December 16, 2010
Last Updated: July 16, 2014
Health Authority: Austria: Agency for Health and Food Safety
Bulgaria: Bulgarian Drug Agency
Croatia: Ministry of Health and Social Care
Czech Republic: State Institute for Drug Control
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Federal Institute for Drugs and Medical Devices
Hungary: National Institute of Pharmacy
Moldova: Medicines Agency
Poland: The Central Register of Clinical Trials
Romania: National Medicines Agency
Russia: Ministry of Health of the Russian Federation
Serbia: Medicines and Medical Devices Agency
Spain: Agencia Española de Medicamentos y Productos Sanitarios

Keywords provided by Grünenthal GmbH:
chronic pain
tumour related pain

Additional relevant MeSH terms:
Chronic Pain
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms

ClinicalTrials.gov processed this record on October 20, 2014